PEGVISOMANT Side Effects

7013092-0 | Cholelithiasis
on Sep 13, 2010 Male patient from UNITED STATES , weighting 239.0 lb, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). Patient experienced the following unwanted or unexpected effects: cholelithiasis. Pegvisomant dosage: 10 Mg, 1x/day. During the same period patient was treated with ADENOSYLCOBALAMIN/FOLIC ACID/METHYLCOBALAMIN/VIT B1/VIT B2/ VIT B6 (Unk) (View Adenosylcobalamin/folic Acid/methylcobalamin/vit B1/vit B2/ Vit B6 Review and Adenosylcobalamin/folic Acid/methylcobalamin/vit B1/vit B2/ Vit B6 Label ), VITAMIN D (Unk) (View Vitamin D Review and Vitamin D Label ), ISORDIL (Unk) (View Isordil Review and Isordil Label ), DILTIAZEM (Unk) (View Diltiazem Review and Diltiazem Label ), HYOSCYAMINE (Unk) (View Hyoscyamine Review and Hyoscyamine Label ), PREVACID (Unk) (View Prevacid Review and Prevacid Label ), PLAVIX (Unk) (View Plavix Review and Plavix Label ), ACETYLSALICYLIC ACID (Unk) (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ). Patient was hospitalized.

7006120-X | Hypercholesterolaemia
Patient was taking Pegvisomant (View Usage). Patient had the following side effects: hypercholesterolaemia on Sep 09, 2010 from JAPAN Additional patient health information: Male patient , 41 years of age, weighting 194.0 lb, was diagnosed with acromegaly and. Pegvisomant dosage: 40 Mg, 1x/day. During the same period patient was treated with SANDOSTATIN (30 Mg, Every 4 Weeks) (View Sandostatin Review and Sandostatin Label ), CABASER (Unk) (View Cabaser Review and Cabaser Label ), THYRADIN (Unk) (View Thyradin Review and Thyradin Label ), LEVOTHYROXINE (Unk) (View Levothyroxine Review and Levothyroxine Label ).

6972721-8 | Condition Aggravated, Pituitary Tumour Benign
Adverse event was reported on Aug 31, 2010 by a Male patient taking Pegvisomant (View Usage) (Dosage: 20 Mg, 1x/day) was diagnosed with acromegaly and. Location: GERMANY , 69 years of age, weighting 163.1 lb, After Pegvisomant was administered, patient had the following side effects: condition aggravated, pituitary tumour benign. During the same period patient was treated with LEVOTHYROXINE SODIUM (Unk) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), RAMIPRIL (Unk) (View Ramipril Review and Ramipril Label ), SIMVASTATIN (Unk) (View Simvastatin Review and Simvastatin Label ), TESTOSTERONE (Unk) (View Testosterone Review and Testosterone Label ). Patient was hospitalized.

6938315-5 | Neoplasm Malignant
on Aug 12, 2010 Male patient from GERMANY , 55 years of age, weighting 204.4 lb, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). Patient experienced the following unwanted or unexpected effects: neoplasm malignant. Pegvisomant dosage: 10 Mg, 1x/day. During the same period patient was treated with VITAMIN D (800 Iu, 1x/day) (View Vitamin D Review and Vitamin D Label ), CALCIUM (1000 Mg, 1x/day) (View Calcium Review and Calcium Label ). Patient was hospitalized.


6927924-5 |
on Aug 06, 2010 Male patient from NETHERLANDS , 72 years of age, weighting 198.4 lb, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). . Pegvisomant dosage: Unk. During the same period patient was treated with LISINOPRIL (20 Mg, Unk) (View Lisinopril Review and Lisinopril Label ), ACENOCOUMAROL (Unk) (View Acenocoumarol Review and Acenocoumarol Label ), ANDROGEL (50 Unk, Unk) (View Androgel Review and Androgel Label ).

6847467-7 |
Patient was taking Pegvisomant (View Usage). on Jul 06, 2010 from NETHERLANDS Additional patient health information: Male patient , 72 years of age, weighting 198.4 lb, was diagnosed with acromegaly and. Pegvisomant dosage: Unk. During the same period patient was treated with LISINOPRIL (Unk) (View Lisinopril Review and Lisinopril Label ), ACENOCOUMAROL (Unk) (View Acenocoumarol Review and Acenocoumarol Label ), ANDROGEL (Unk) (View Androgel Review and Androgel Label ).

6836304-2 | Pituitary Tumour Recurrent
Adverse event was reported on Jul 06, 2010 by a Female patient taking Pegvisomant (View Usage) (Dosage: 10 Mg, Unk) was diagnosed with acromegaly and. Location: FRANCE , 45 years of age, weighting 209.4 lb, Patient experienced the following unwanted or unexpected effects: pituitary tumour recurrent. During the same period patient was treated with PERINDOPRIL ERBUMINE/INDAPAMIDE HEMIHYDRATE (Unk) (View Perindopril Erbumine/indapamide Hemihydrate Review and Perindopril Erbumine/indapamide Hemihydrate Label ), LEVOTHYROXINE (Unk) (View Levothyroxine Review and Levothyroxine Label ), HYDROCORTISONE (Unk) (View Hydrocortisone Review and Hydrocortisone Label ), TESTOSTERONE UNDECANOATE (Unk) (View Testosterone Undecanoate Review and Testosterone Undecanoate Label ). Patient was hospitalized.

6817807-3 |
on Jun 29, 2010 Male patient from NETHERLANDS , 72 years of age, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). . Pegvisomant dosage: Unk. During the same period patient was treated with LISINOPRIL (Unk) (View Lisinopril Review and Lisinopril Label ), ACENOCOUMAROL (Unk) (View Acenocoumarol Review and Acenocoumarol Label ), ANDROGEL (Unk) (View Androgel Review and Androgel Label ).

6817671-2 | Lacunar Infarction
on Jun 28, 2010 Male patient from SPAIN , 64 years of age, weighting 191.8 lb, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). After Pegvisomant was administered, patient had the following side effects: lacunar infarction. Pegvisomant dosage: 15 Mg, 1x/day. During the same period patient was treated with METFORMIN HYDROCHLORIDE (Unk) (View Metformin Hydrochloride Review and Metformin Hydrochloride Label ), AMLODIPINE OROTATE (Unk) (View Amlodipine Orotate Review and Amlodipine Orotate Label ), ACETYLSALICYLIC ACID (Unk) (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ), EPROSARTAN (View Eprosartan Review and Eprosartan Label ), ATORVASTATIN CALCIUM (Unk) (View Atorvastatin Calcium Review and Atorvastatin Calcium Label ). Patient was hospitalized.

6817645-1 | Pituitary Tumour Recurrent
Patient was taking Pegvisomant (View Usage). Patient experienced the following unwanted or unexpected effects: pituitary tumour recurrent on Jun 29, 2010 from FRANCE Additional patient health information: Male patient , 45 years of age, was diagnosed with acromegaly and. Pegvisomant dosage: Unk. Patient was hospitalized.

6812989-1 | Cholelithiasis
Adverse event was reported on Jun 28, 2010 by a Male patient taking Pegvisomant (View Usage) (Dosage: 10 Mg, 1x/day) was diagnosed with acromegaly and. Location: UNITED STATES , weighting 243.8 lb, Patient had the following side effects: cholelithiasis. During the same period patient was treated with ADENOSYLCOBALAMIN/FOLIC ACID/METHYLCOBALAMIN/VIT B1/VIT B2/ VIT B6 (Unk) (View Adenosylcobalamin/folic Acid/methylcobalamin/vit B1/vit B2/ Vit B6 Review and Adenosylcobalamin/folic Acid/methylcobalamin/vit B1/vit B2/ Vit B6 Label ), VITAMIN D (Unk) (View Vitamin D Review and Vitamin D Label ), ISORDIL (Unk) (View Isordil Review and Isordil Label ), DILTIAZEM (Unk) (View Diltiazem Review and Diltiazem Label ), HYOSCYAMINE (Unk) (View Hyoscyamine Review and Hyoscyamine Label ), PREVACID (Unk) (View Prevacid Review and Prevacid Label ), PLAVIX (Unk) (View Plavix Review and Plavix Label ), ASPIRIN (Unk) (View Aspirin Review and Aspirin Label ). Patient was hospitalized.

6775597-7 | Disease Progression
on Jun 11, 2010 Male patient from ITALY , 57 years of age, weighting 234.8 lb, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). After Pegvisomant was administered, patient had the following side effects: disease progression. Pegvisomant dosage: 20 Mg, Once A Day. During the same period patient was treated with CUMADIN (Unk) (View Cumadin Review and Cumadin Label ), TAREG (80) (View Tareg Review and Tareg Label ), LASITONE (Unk) (View Lasitone Review and Lasitone Label ), LEVOTHYROXINE SODIUM (25) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), CORDARONE (Unk) (View Cordarone Review and Cordarone Label ), LANOXIN (0.125) (View Lanoxin Review and Lanoxin Label ).

6770470-2 | Haemoptysis, Pneumonia
on Jun 08, 2010 Female patient from DENMARK , 81 years of age, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). Patient experienced the following unwanted or unexpected effects: haemoptysis, pneumonia (What is pneumonia?). Pegvisomant dosage: 10 Mg, 1x/day. During the same period patient was treated with SANDOSTATIN (30 Mg, Monthly) (View Sandostatin Review and Sandostatin Label ), CIPRALEX (20 Mg, 1x/day) (View Cipralex Review and Cipralex Label ), COZAAR (Unk) (View Cozaar Review and Cozaar Label ), HYDROKORTISON (10 Mg, 1x/day) (View Hydrokortison Review and Hydrokortison Label ), SERETIDE (Two Dose, 2x/day) (View Seretide Review and Seretide Label ). Patient was hospitalized.

6762854-3 |
Patient was taking Pegvisomant (View Usage). on Jun 01, 2010 from ITALY Additional patient health information: Male patient , 57 years of age, weighting 234.8 lb, was diagnosed with acromegaly and. Pegvisomant dosage: 20 Mg, Once A Day. During the same period patient was treated with CUMADIN (View Cumadin Review and Cumadin Label ), TAREG (80) (View Tareg Review and Tareg Label ), LASITONE (View Lasitone Review and Lasitone Label ), LEVOTHYROXINE SODIUM (25) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), CORDARONE (View Cordarone Review and Cordarone Label ), LANOXIN (0.125) (View Lanoxin Review and Lanoxin Label ).

6760666-8 | Haemoptysis, Pneumonia
Adverse event was reported on May 27, 2010 by a Female patient taking Pegvisomant (View Usage) (Dosage: 10 Mg, 1x/day) was diagnosed with acromegaly and. Location: DENMARK , 81 years of age, After Pegvisomant was administered, patient had the following side effects: haemoptysis, pneumonia (What is pneumonia?). During the same period patient was treated with SANDOSTATIN (30 Mg, Monthly) (View Sandostatin Review and Sandostatin Label ), CIPRALEX (20 Mg, 1x/day) (View Cipralex Review and Cipralex Label ), COZAAR (Unk) (View Cozaar Review and Cozaar Label ), HYDROKORTISON (10 Mg, 1x/day) (View Hydrokortison Review and Hydrokortison Label ), SERETIDE (Two Dose, 2x/day) (View Seretide Review and Seretide Label ). Patient was hospitalized.

6760619-X | Neoplasm Progression
on May 27, 2010 Male patient from GERMANY , 58 years of age, weighting 220.5 lb, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). Patient experienced the following unwanted or unexpected effects: neoplasm progression. Pegvisomant dosage: 30 Mg, 1x/day. During the same period patient was treated with MINRIN (Unk) (View Minrin Review and Minrin Label ).

6750295-4 | Haemoptysis, Pneumonia
on May 19, 2010 Female patient from DENMARK , 81 years of age, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). Patient had the following side effects: haemoptysis, pneumonia (What is pneumonia?). Pegvisomant dosage: 10 Mg, 1x/day. During the same period patient was treated with SANDOSTATIN (30 Mg, Monthly) (View Sandostatin Review and Sandostatin Label ), CIPRALEX (20 Mg, 1x/day) (View Cipralex Review and Cipralex Label ), COZAAR (Unk) (View Cozaar Review and Cozaar Label ), HYDROKORTISON (10 Mg, 1x/day) (View Hydrokortison Review and Hydrokortison Label ), SERETIDE (Two Dose, 2x/day) (View Seretide Review and Seretide Label ). Patient was hospitalized.

6747150-2 | Colitis
Patient was taking Pegvisomant (View Usage). After Pegvisomant was administered, patient had the following side effects: colitis on May 17, 2010 from GERMANY Additional patient health information: Male patient , 65 years of age, weighting 172.0 lb, was diagnosed with acromegaly, hypertension, lipid metabolism disorder and. Pegvisomant dosage: 20 Mg, 1x/day. During the same period patient was treated with CONCOR (2.5 Mg, Unk) (View Concor Review and Concor Label ), ASPIRIN (100 Mg, Unk) (View Aspirin Review and Aspirin Label ), PLAVIX (Unk) (View Plavix Review and Plavix Label ), SIMVASTATIN (20 Mg, Unk) (View Simvastatin Review and Simvastatin Label ), RAMIPRIL (20 Mg, Unk) (View Ramipril Review and Ramipril Label ). Patient was hospitalized.

6734982-X | Cholecystitis Acute, Septic Shock
Adverse event was reported on May 10, 2010 by a Female patient taking Pegvisomant (View Usage) (Dosage: 10 Mg, Daily) was diagnosed with acromegaly and. Location: FRANCE , 60 years of age, weighting 165.3 lb, Patient experienced the following unwanted or unexpected effects: cholecystitis acute, septic shock. During the same period patient was treated with ATORVASTATIN (Unk) (View Atorvastatin Review and Atorvastatin Label ), LEVOTHYROXINE SODIUM (Unk) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), TRIMETAZIDINE (Unk) (View Trimetazidine Review and Trimetazidine Label ), LIPANTHYL (Unk) (View Lipanthyl Review and Lipanthyl Label ), GLUCOR (Unk) (View Glucor Review and Glucor Label ), HYDROCORTISONE (Unk) (View Hydrocortisone Review and Hydrocortisone Label ), ASPIRIN (Unk) (View Aspirin Review and Aspirin Label ), ESOMEPRAZOLE (Unk) (View Esomeprazole Review and Esomeprazole Label ). Patient was hospitalized.

6734958-2 | Exeresis
on May 10, 2010 Male patient from FRANCE , 42 years of age, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). Patient had the following side effects: exeresis. Pegvisomant dosage: 20 Mg, 1x/day. Patient was hospitalized.

6724576-4 | Condition Aggravated, Pituitary Tumour Benign
on May 12, 2010 Male patient from GERMANY , 69 years of age, weighting 163.1 lb, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). After Pegvisomant was administered, patient had the following side effects: condition aggravated, pituitary tumour benign. Pegvisomant dosage: 20 Mg, 1x/day. During the same period patient was treated with LEVOTHYROXINE SODIUM (Unk) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), RAMIPRIL (Unk) (View Ramipril Review and Ramipril Label ), SIMVASTATIN (Unk) (View Simvastatin Review and Simvastatin Label ), TESTOSTERONE (Unk) (View Testosterone Review and Testosterone Label ).

6684051-2 | Gastrointestinal Haemorrhage
Patient was taking Pegvisomant (View Usage). Patient experienced the following unwanted or unexpected effects: gastrointestinal haemorrhage on Apr 06, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 231.5 lb, was diagnosed with prostate cancer (What is prostate cancer?), dyspnoea, hypertension and. Pegvisomant dosage: 10 Mg, 1x/day. During the same period patient was treated with CP 751,871 (2228 Mg, Day 1 And 2 Of Cycle 1, Day 1 Of Cycle 2 And Every 3 Weeks Onwards Or Every 3 Weeks) (View Cp-751,871 Review and Cp-751,871 Label ), ADVAIR DISKUS 100/50 (View Advair Diskus 100/50 Review and Advair Diskus 100/50 Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ), ZIAC (View Ziac Review and Ziac Label ), CALCITRIOL (View Calcitriol Review and Calcitriol Label ), CALCIUM (View Calcium Review and Calcium Label ), VITAMIN D3 (View Vitamin D3 Review and Vitamin D3 Label ), VALSARTAN (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

6671891-9 | Gastrointestinal Haemorrhage
Adverse event was reported on Mar 26, 2010 by a Male patient taking Pegvisomant (View Usage) (Dosage: 10 Mg, 1x/day) was diagnosed with prostate cancer (What is prostate cancer?), dyspnoea, hypertension and. Location: UNITED STATES , weighting 231.5 lb, Patient had the following side effects: gastrointestinal haemorrhage. During the same period patient was treated with CP 751,871 (2228 Mg, Day 1 And 2 Of Cycle 1, Day 1 Of Cycle 2 And Every 3 Weeks Onwards Or Every 3 Weeks) (View Cp-751,871 Review and Cp-751,871 Label ), ADVAIR DISKUS 100/50 (View Advair Diskus 100/50 Review and Advair Diskus 100/50 Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ), ZIAC (View Ziac Review and Ziac Label ), CALCITRIOL (View Calcitriol Review and Calcitriol Label ), CALCIUM (View Calcium Review and Calcium Label ), VITAMIN D3 (View Vitamin D3 Review and Vitamin D3 Label ), VALSARTAN (View Valsartan Review and Valsartan Label ). Patient was hospitalized.

6662070-X | Endometrial Cancer, Phlebitis, Pulmonary Embolism
on Mar 19, 2010 Female patient from FRANCE , 62 years of age, weighting 169.8 lb, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). After Pegvisomant was administered, patient had the following side effects: endometrial cancer, phlebitis, pulmonary embolism (What is pulmonary embolism?). Pegvisomant dosage: 15 Mg, 1x/day. During the same period patient was treated with NOCTRAN 10 (Unk) (View Noctran 10 Review and Noctran 10 Label ), LIPANOR (Unk) (View Lipanor Review and Lipanor Label ), HYZAAR (Unk) (View Hyzaar Review and Hyzaar Label ), TENORMIN (Unk) (View Tenormin Review and Tenormin Label ), STAGID (Unk) (View Stagid Review and Stagid Label ). Patient was hospitalized.

6636482-4 | Endometrial Cancer, Phlebitis, Pulmonary Embolism
on Mar 04, 2010 Female patient from FRANCE , 62 years of age, weighting 169.8 lb, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). Patient experienced the following unwanted or unexpected effects: endometrial cancer, phlebitis, pulmonary embolism (What is pulmonary embolism?). Pegvisomant dosage: 15 Mg, 1x/day. During the same period patient was treated with NOCTRAN 10 (Unk) (View Noctran 10 Review and Noctran 10 Label ), LIPANOR (Unk) (View Lipanor Review and Lipanor Label ), HYZAAR (Unk) (View Hyzaar Review and Hyzaar Label ), TENORMIN (Unk) (View Tenormin Review and Tenormin Label ), STAGID (Unk) (View Stagid Review and Stagid Label ). Patient was hospitalized.

6631629-8 | Condition Aggravated, Pituitary Tumour Benign
Patient was taking Pegvisomant (View Usage). Patient had the following side effects: condition aggravated, pituitary tumour benign on Mar 01, 2010 from GERMANY Additional patient health information: Male patient , 69 years of age, weighting 163.1 lb, was diagnosed with acromegaly and. Pegvisomant dosage: 20 Mg, 1x/day. During the same period patient was treated with L THYROXIN (Unk) (View L-thyroxin Review and L-thyroxin Label ), RAMIPRIL (Unk) (View Ramipril Review and Ramipril Label ), SIMVASTATIN (Unk) (View Simvastatin Review and Simvastatin Label ), TESTOSTERONE (Unk) (View Testosterone Review and Testosterone Label ).

6616164-5 | Hypercholesterolaemia
Adverse event was reported on Feb 22, 2010 by a Male patient taking Pegvisomant (View Usage) (Dosage: 40 Mg, 1x/day) was diagnosed with acromegaly and. Location: JAPAN , 41 years of age, weighting 194.0 lb, After Pegvisomant was administered, patient had the following side effects: hypercholesterolaemia. During the same period patient was treated with SANDOSTATIN (30 Mg, Every 4 Weeks) (View Sandostatin Review and Sandostatin Label ), CABASER (Unk) (View Cabaser Review and Cabaser Label ), THYRADIN (Unk) (View Thyradin Review and Thyradin Label ), LEVOTHYROXINE (Unk) (View Levothyroxine Review and Levothyroxine Label ).

6610159-3 | Endometrial Cancer, Phlebitis, Pulmonary Embolism
on Feb 18, 2010 Female patient from FRANCE , 62 years of age, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). Patient experienced the following unwanted or unexpected effects: endometrial cancer, phlebitis, pulmonary embolism (What is pulmonary embolism?). Pegvisomant dosage: Unk. Patient was hospitalized.

6564833-8 | Neoplasm Recurrence
on Jan 21, 2010 Male patient from GERMANY , 41 years of age, weighting 196.2 lb, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). Patient had the following side effects: neoplasm recurrence. Pegvisomant dosage: 35 Mg, 1x/day. During the same period patient was treated with THYRONAJOD (View Thyronajod Review and Thyronajod Label ), TESTOSTERONE (View Testosterone Review and Testosterone Label ), HYDROCORTISONE (View Hydrocortisone Review and Hydrocortisone Label ), ATACAND HCT (View Atacand Hct Review and Atacand Hct Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ). Patient was hospitalized.

6483436-7 | Cholecystitis Acute, Septic Shock
Patient was taking Pegvisomant (View Usage). After Pegvisomant was administered, patient had the following side effects: cholecystitis acute, septic shock on Nov 27, 2009 from FRANCE Additional patient health information: Female patient , 60 years of age, weighting 165.3 lb, was diagnosed with acromegaly and. Pegvisomant dosage: 10 Mg, Daily. During the same period patient was treated with LEVOTHYROXINE SODIUM (Unk) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), TRIMETAZIDINE (Unk) (View Trimetazidine Review and Trimetazidine Label ), LIPANTHYL (Unk) (View Lipanthyl Review and Lipanthyl Label ), GLUCOR (Unk) (View Glucor Review and Glucor Label ), HYDROCORTISONE (Unk) (View Hydrocortisone Review and Hydrocortisone Label ), KARDEGIC (Unk) (View Kardegic Review and Kardegic Label ). Patient was hospitalized.

6475842-1 | Blood Alkaline Phosphatase Increased, Cholecystectomy, Cholecystitis Acute, Cholelithiasis
Adverse event was reported on Nov 25, 2009 by a Male patient taking Pegvisomant (View Usage) (Dosage: ) was diagnosed with acromegaly and. Location: UNITED KINGDOM , 60 years of age, Patient experienced the following unwanted or unexpected effects: blood alkaline phosphatase increased, cholecystectomy, cholecystitis acute, cholelithiasis. During the same period patient was treated with SANDOSTATIN LAR (27 Mg, Monthly) (View Sandostatin Lar Review and Sandostatin Lar Label ). Patient was hospitalized.

6474188-5 |
on Nov 24, 2009 Male patient from SPAIN , 55 years of age, weighting 200.6 lb, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). . Pegvisomant dosage: 30 Mg, 1x/day. During the same period patient was treated with METFORMIN (1700 Mg, 1x/day) (View Metformin Review and Metformin Label ), ACETYLSALICYLIC ACID (100 Mg, 1x/day) (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ), ATORVASTATIN (20 Mg, 1x/day) (View Atorvastatin Review and Atorvastatin Label ), TESTOSTERONE UNDECANOATE (Every 3 Months) (View Testosterone Undecanoate Review and Testosterone Undecanoate Label ), ENALAPRIL (20 Mg, 1x/day) (View Enalapril Review and Enalapril Label ), BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE (1 Tablet, 1x/day) (View Bisoprolol Fumarate And Hydrochlorothiazide Review and Bisoprolol Fumarate And Hydrochlorothiazide Label ), SOMATULINA (90 Mg, Cyclic) (View Somatulina Review and Somatulina Label ).

6466839-6 | Blood Bilirubin Increased, Cholecystitis Acute
on Nov 20, 2009 Male patient from UNITED KINGDOM , 45 years of age, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). After Pegvisomant was administered, patient had the following side effects: blood bilirubin increased, cholecystitis acute. Pegvisomant dosage: . During the same period patient was treated with SANDOSTATIN LAR (27 Mg, Monthly) (View Sandostatin Lar Review and Sandostatin Lar Label ). Patient was hospitalized.

6466838-4 | Biliary Colic, Cholelithiasis, Insulin-like Growth Factor Increased
Patient was taking Pegvisomant (View Usage). Patient experienced the following unwanted or unexpected effects: biliary colic, cholelithiasis, insulin-like growth factor increased on Nov 18, 2009 from UNITED KINGDOM Additional patient health information: Male patient , 28 years of age, was diagnosed with acromegaly and. Pegvisomant dosage: . During the same period patient was treated with SANDOSTATIN LAR (Unk) (View Sandostatin Lar Review and Sandostatin Lar Label ). Patient was hospitalized.

6466837-2 | Blood Alkaline Phosphatase Increased, Cholecystectomy, Cholecystitis Acute, Cholelithiasis
Adverse event was reported on Nov 20, 2009 by a Male patient taking Pegvisomant (View Usage) (Dosage: ) was diagnosed with acromegaly and. Location: UNITED KINGDOM , 60 years of age, Patient had the following side effects: blood alkaline phosphatase increased, cholecystectomy, cholecystitis acute, cholelithiasis. During the same period patient was treated with SANDOSTATIN LAR (27 Mg, Monthly) (View Sandostatin Lar Review and Sandostatin Lar Label ). Patient was hospitalized.

6465590-6 | Cholecystitis Acute, Cholelithiasis, Diarrhoea, Eructation, Insulin-like Growth Factor Increased, Nausea
on Nov 17, 2009 Male patient from UNITED KINGDOM , 58 years of age, weighting 194.0 lb, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). After Pegvisomant was administered, patient had the following side effects: cholecystitis acute, cholelithiasis, diarrhoea, eructation, insulin-like growth factor increased, nausea (What is nausea?). Pegvisomant dosage: Unk. During the same period patient was treated with SANDOSTATIN LAR (27 Mg, Monthly) (View Sandostatin Lar Review and Sandostatin Lar Label ), HYDROCORTISONE (Unk) (View Hydrocortisone Review and Hydrocortisone Label ), TESTOSTERONE (Unk) (View Testosterone Review and Testosterone Label ). Patient was hospitalized.

6456189-6 | Cholecystitis Acute
on Oct 29, 2009 Male patient from FRANCE , 61 years of age, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). Patient experienced the following unwanted or unexpected effects: cholecystitis acute. Pegvisomant dosage: Unk. Patient was hospitalized.

6434791-5 | Cholecystitis Acute
Patient was taking Pegvisomant (View Usage). Patient had the following side effects: cholecystitis acute on Oct 29, 2009 from FRANCE Additional patient health information: Male patient , 61 years of age, was diagnosed with acromegaly and. Pegvisomant dosage: Unk. Patient was hospitalized.

6434457-1 | Escherichia Sepsis, Septic Shock
Adverse event was reported on Oct 29, 2009 by a Male patient taking Pegvisomant (View Usage) (Dosage: Unk) was diagnosed with acromegaly and. Location: FRANCE , 60 years of age, After Pegvisomant was administered, patient had the following side effects: escherichia sepsis, septic shock. Patient was hospitalized.

6432562-7 |
on Oct 28, 2009 Male patient from SPAIN , 55 years of age, weighting 200.6 lb, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). . Pegvisomant dosage: 30 Mg, 1x/day. During the same period patient was treated with METFORMIN (1700 Mg, 1x/day) (View Metformin Review and Metformin Label ), ACETYLSALICYLIC ACID (100 Mg, 1x/day) (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ), ATORVASTATIN (20 Mg, 1x/day) (View Atorvastatin Review and Atorvastatin Label ), TESTOSTERONE UNDECANOATE (Every 3 Months) (View Testosterone Undecanoate Review and Testosterone Undecanoate Label ), ENALAPRIL (20 Mg, 1x/day) (View Enalapril Review and Enalapril Label ), BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE (1 Tablet, 1x/day) (View Bisoprolol Fumarate And Hydrochlorothiazide Review and Bisoprolol Fumarate And Hydrochlorothiazide Label ).

6432364-1 | Hypercholesterolaemia
on Oct 28, 2009 Male patient from JAPAN , 41 years of age, weighting 194.0 lb, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). Patient had the following side effects: hypercholesterolaemia. Pegvisomant dosage: 40 Mg, 1x/day. During the same period patient was treated with SANDOSTATIN (30 Mg, Every 4 Weeks) (View Sandostatin Review and Sandostatin Label ), CABASER (Unk) (View Cabaser Review and Cabaser Label ), THYRADIN (Unk) (View Thyradin Review and Thyradin Label ), LEVOTHYROXINE (Unk) (View Levothyroxine Review and Levothyroxine Label ).

6405409-2 | Haemoptysis, Pneumonia
Patient was taking Pegvisomant (View Usage). After Pegvisomant was administered, patient had the following side effects: haemoptysis, pneumonia (What is pneumonia?) on Oct 07, 2009 from DENMARK Additional patient health information: Female patient , 81 years of age, was diagnosed with acromegaly and. Pegvisomant dosage: 10 Mg, 1x/day. During the same period patient was treated with SANDOSTATIN (30 Mg, Monthly) (View Sandostatin Review and Sandostatin Label ), CIPRALEX (20 Mg, 1x/day) (View Cipralex Review and Cipralex Label ), COZAAR (Unk) (View Cozaar Review and Cozaar Label ), HYDROKORTISON (10 Mg, 1x/day) (View Hydrokortison Review and Hydrokortison Label ), SERETIDE (Two Dose, 2x/day) (View Seretide Review and Seretide Label ). Patient was hospitalized.

6397211-5 | Hypercholesterolaemia
Adverse event was reported on Sep 30, 2009 by a Female patient taking Pegvisomant (View Usage) (Dosage: 40 Mg, 1x/day) was diagnosed with acromegaly and. Location: JAPAN , 41 years of age, Patient experienced the following unwanted or unexpected effects: hypercholesterolaemia. During the same period patient was treated with SANDOSTATIN (30 Mg, Every 4 Weeks) (View Sandostatin Review and Sandostatin Label ), CABASER (Unk) (View Cabaser Review and Cabaser Label ), THYRADIN (Unk) (View Thyradin Review and Thyradin Label ), LEVOTHYROXINE (Unk) (View Levothyroxine Review and Levothyroxine Label ).

6384090-5 | Oesophageal Carcinoma
on Sep 17, 2009 Female patient from ITALY , 75 years of age, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). Patient had the following side effects: oesophageal carcinoma. Pegvisomant dosage: 10 Mg, 1x/day. During the same period patient was treated with ACETYLSALICYLIC ACID (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ), PERINDOPRIL (View Perindopril Review and Perindopril Label ), ENALAPRIL (View Enalapril Review and Enalapril Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), NEBIVOLOL (View Nebivolol Review and Nebivolol Label ). Patient was hospitalized and became disabled.

6282207-4 | Dacryostenosis Acquired, Haemorrhage
on Jul 13, 2009 Female patient from UNITED KINGDOM , 75 years of age, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). After Pegvisomant was administered, patient had the following side effects: dacryostenosis acquired, haemorrhage. Pegvisomant dosage: 10 Mg, 1x/day. During the same period patient was treated with ATENOLOL (Unk) (View Atenolol Review and Atenolol Label ), NICORANDIL (Unk) (View Nicorandil Review and Nicorandil Label ), ACETYLSALICYLIC ACID (Unk) (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ), FRUSEMIDE (Unk) (View Frusemide Review and Frusemide Label ). Patient was hospitalized.

6277449-8 | Oesophageal Carcinoma
Patient was taking Pegvisomant (View Usage). Patient experienced the following unwanted or unexpected effects: oesophageal carcinoma on Jul 10, 2009 from ITALY Additional patient health information: Female patient , 75 years of age, was diagnosed with acromegaly and. Pegvisomant dosage: 10 Mg, 1x/day. During the same period patient was treated with ACETYLSALICYLIC ACID (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ), PERINDOPRIL (View Perindopril Review and Perindopril Label ), ENALAPRIL (View Enalapril Review and Enalapril Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), NEBIVOLOL (View Nebivolol Review and Nebivolol Label ). Patient was hospitalized and became disabled.

6268453-4 | Prostate Cancer
Adverse event was reported on Jul 02, 2009 by a Female patient taking Pegvisomant (View Usage) (Dosage: 5 Unk, Unk) was diagnosed with acromegaly and. Location: GERMANY , 73 years of age, Patient had the following side effects: prostate cancer (What is prostate cancer?). During the same period patient was treated with TESTOSTERONE CIPIONATE (View Testosterone Cipionate Review and Testosterone Cipionate Label ), ATACAND (View Atacand Review and Atacand Label ), GELOMYRTOL (View Gelomyrtol Review and Gelomyrtol Label ), VITAMIN D (View Vitamin D Review and Vitamin D Label ), CALCIUM (View Calcium Review and Calcium Label ). Patient was hospitalized.

6265475-4 | Colitis
on Jul 01, 2009 Female patient from GERMANY , 65 years of age, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). After Pegvisomant was administered, patient had the following side effects: colitis. Pegvisomant dosage: 20 Mg, 1x/day. Patient was hospitalized.

6263672-5 | Dacryostenosis Acquired, Haemorrhage
on Jun 29, 2009 Female patient from UNITED KINGDOM , 75 years of age, was diagnosed with acromegaly and was treated with Pegvisomant (View Usage). Patient experienced the following unwanted or unexpected effects: dacryostenosis acquired, haemorrhage. Pegvisomant dosage: 10 Mg, 1x/day. During the same period patient was treated with ATENOLOL (Unk) (View Atenolol Review and Atenolol Label ), NICORANDIL (Unk) (View Nicorandil Review and Nicorandil Label ), ACETYLSALICYLIC ACID (Unk) (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ), FRUSEMIDE (Unk) (View Frusemide Review and Frusemide Label ). Patient was hospitalized.

6219214-3 | Anaemia, Dacryostenosis Acquired, Haemorrhage
Patient was taking Pegvisomant (View Usage). Patient had the following side effects: anaemia, dacryostenosis acquired, haemorrhage on May 28, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 75 years of age, . Pegvisomant dosage: Unk. During the same period patient was treated with ATENOLOL (Unk) (View Atenolol Review and Atenolol Label ), NICORANDIL (Unk) (View Nicorandil Review and Nicorandil Label ), ACETYLSALICYLIC ACID (Unk) (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ), FRUSEMIDE (Unk) (View Frusemide Review and Frusemide Label ). Patient was hospitalized.